Fetal gene therapy for neurodegenerative disease of infants

For inherited genetic diseases, fetal gene therapy offers the potential of prophylaxis against early, irreversible and lethal pathological change. To explore this, we studied neuronopathic Gaucher disease (nGD), caused by mutations in GBA. In adult patients, the milder form presents with hepatomegaly, splenomegaly and occasional lung and bone disease; this is managed, symptomatically, by enzyme replacement therapy. The acute childhood lethal form of nGD is untreatable since enzyme cannot cross the blood–brain barrier. Patients with nGD exhibit signs consistent with hindbrain neurodegeneration, including neck hyperextension, strabismus and, often, fatal apnea1. We selected a mouse model of nGD carrying a loxP-flanked neomycin disruption of Gba plus Cre recombinase regulated by the keratinocyte-specific K14 promoter. Exclusive skin expression of Gba prevents fatal neonatal dehydration. Instead, mice develop fatal neurodegeneration within 15 days2. Using this model, fetal intracranial injection of adeno-associated virus (AAV) vector reconstituted neuronal glucocerebrosidase expression. Mice lived for up to at least 18 weeks, were fertile and fully mobile. Neurodegeneration was abolished and neuroinflammation ameliorated. Neonatal intervention also rescued mice but less effectively. As the next step to clinical translation, we also demonstrated the feasibility of ultrasound-guided global AAV gene transfer to fetal macaque brains.In utero GBA gene therapy extends lifespan and provides long-lasting phenotypic amelioration in a mouse model of neuronopathic Gaucher disease. Fetal ultrasound-guided in utero gene vector delivery is also achieved in the non-human primate brain.

[1]  J. Cooper,et al.  Spatial and temporal correlation between neuron loss and neuroinflammation in a mouse model of neuronopathic Gaucher disease. , 2011, Human molecular genetics.

[2]  M. Dallman,et al.  In utero gene transfer of human factor IX to fetal mice can induce postnatal tolerance of the exogenous clotting factor. , 2003, Blood.

[3]  J Montane,et al.  High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency , 2010, Gene Therapy.

[4]  S. Ojeda,et al.  Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[5]  Stacy D. Grunke,et al.  Intracerebroventricular viral injection of the neonatal mouse brain for persistent and widespread neuronal transduction. , 2014, Journal of Visualized Experiments.

[6]  C. von Kalle,et al.  Stable human FIX expression after 0.9G intrauterine gene transfer of self-complementary adeno-associated viral vector 5 and 8 in macaques. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  D. Zeevi,et al.  Proof-of-principle rapid noninvasive prenatal diagnosis of autosomal recessive founder mutations. , 2015, The Journal of clinical investigation.

[8]  E. Sidransky,et al.  Type 2 Gaucher disease: phenotypic variation and genotypic heterogeneity. , 2011, Blood cells, molecules & diseases.

[9]  R. Dwek,et al.  Analysis of fluorescently labeled glycosphingolipid-derived oligosaccharides following ceramide glycanase digestion and anthranilic acid labeling. , 2004, Analytical biochemistry.

[10]  L M Cruz-Orive,et al.  Estimation of surface area from vertical sections , 1986, Journal of microscopy.

[11]  L. Andrews,et al.  Prenatal gene transfer: Scientific, medical, and ethical issues: A report of the recombinant DNA advisory committee , 2000 .

[12]  S. Dunnett,et al.  Motor Coordination and Balance in Rodents , 2001, Current protocols in neuroscience.

[13]  K. Mills,et al.  The synthesis of internal standards for the quantitative determination of sphingolipids by tandem mass spectrometry. , 2005, Rapid communications in mass spectrometry : RCM.

[14]  N. LeLeiko,et al.  Resting energy expenditure in Gaucher's disease type 1: effect of Gaucher's cell burden on energy requirements. , 1989, Metabolism: clinical and experimental.

[15]  Brian K. Kaspar,et al.  Single‐Dose Gene‐Replacement Therapy for Spinal Muscular Atrophy , 2017, The New England journal of medicine.

[16]  M. Choolani,et al.  Animal models for prenatal gene therapy: the nonhuman primate model. , 2012, Methods in molecular biology.

[17]  M. Choolani,et al.  Systemic delivery of scAAV9 in fetal macaques facilitates neuronal transduction of the central and peripheral nervous systems , 2012, Gene Therapy.

[18]  S. Karlsson,et al.  Murine models of acute neuronopathic Gaucher disease , 2007, Proceedings of the National Academy of Sciences.

[19]  S. Acton,et al.  Robust Cardiomyocyte-Specific Gene Expression Following Systemic Injection of AAV: In Vivo Gene Delivery Follows a Poisson Distribution , 2010, Gene Therapy.

[20]  W. Dupont,et al.  Power and sample size calculations. A review and computer program. , 1990, Controlled clinical trials.

[21]  A. Parker,et al.  Evidence for Contribution of CD4+CD25+ Regulatory T Cells in Maintaining Immune Tolerance to Human Factor IX following Perinatal Adenovirus Vector Delivery , 2015, Journal of immunology research.

[22]  H. Naim,et al.  Intracellular transport of acid β‐glucosidase and lysosome‐associated membrane proteins is affected in Gaucher's disease (G202R mutation) , 1999, The Journal of pathology.

[23]  M. Passini,et al.  Widespread Gene Delivery and Structure-Specific Patterns of Expression in the Brain after Intraventricular Injections of Neonatal Mice with an Adeno-Associated Virus Vector , 2001, Journal of Virology.

[24]  J. Cooper,et al.  Early glial activation, synaptic changes and axonal pathology in the thalamocortical system of Niemann–Pick type C1 mice , 2012, Neurobiology of Disease.

[25]  A. Flake,et al.  In utero stem cell transplantation and gene therapy: Recent progress and the potential for clinical application. , 2016, Best practice & research. Clinical obstetrics & gynaecology.

[26]  A. Merrill,et al.  Neuronal accumulation of glucosylceramide in a mouse model of neuronopathic Gaucher disease leads to neurodegeneration. , 2014, Human molecular genetics.

[27]  J. Cooper,et al.  Intravenous administration of AAV2/9 to the fetal and neonatal mouse leads to differential targeting of CNS cell types and extensive transduction of the nervous system , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[28]  A. Flake.  Stem cell and genetic therapies for the fetus. , 2003, Seminars in pediatric surgery.

[29]  C. Mariano.  The preliminary studies , 2006 .

[30]  H. Gundersen,et al.  The efficiency of systematic sampling in stereology — reconsidered , 1999, Journal of microscopy.

[31]  D. Wenger,et al.  Synthetic substrate ß‐glucosidase activity in leukocytes: A reproducible method for the identification of patients and carriers of Gaucher's disease , 1978 .

[32]  D. Warnock,et al.  Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[33]  Mika Ito,et al.  Persistent Expression of Dopamine-Synthesizing Enzymes 15 Years After Gene Transfer in a Primate Model of Parkinson's Disease. , 2017, Human gene therapy. Clinical development.

[34]  R. Saxena,et al.  Inherited metabolic disorders: prenatal diagnosis of lysosomal storage disorders , 2015, Prenatal diagnosis.

[35]  G. Lipshutz,et al.  Development of operational immunologic tolerance with neonatal gene transfer in nonhuman primates: preliminary studies , 2015, Gene Therapy.

[36]  R. Scheule,et al.  Systemic Delivery of a Glucosylceramide Synthase Inhibitor Reduces CNS Substrates and Increases Lifespan in a Mouse Model of Type 2 Gaucher Disease , 2012, PloS one.

[37]  A. Flake,et al.  Stem cell and genetic therapies for the fetus. , 2013, Seminars in pediatric surgery.

[38]  Y. Hua,et al.  Antisense Oligonucleotides Delivered to the Mouse CNS Ameliorate Symptoms of Severe Spinal Muscular Atrophy , 2011, Science Translational Medicine.

[39]  R. Sidman,et al.  CNS expression of glucocerebrosidase corrects α-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy , 2011, Proceedings of the National Academy of Sciences.

[40]  A. Flake,et al.  Stem cell and genetic therapies for the fetus. , 2010, Seminars in fetal & neonatal medicine.

[41]  J. Cooper,et al.  In utero administration of Ad5 and AAV pseudotypes to the fetal brain leads to efficient, widespread and long-term gene expression , 2011, Gene Therapy.

[42]  S. Kaler,et al.  Fetal Brain-directed AAV Gene Therapy Results in Rapid, Robust, and Persistent Transduction of Mouse Choroid Plexus Epithelia , 2013, Molecular therapy. Nucleic acids.

[43]  A. Tamas,et al.  Neurological reflexes and early motor behavior in rats subjected to neonatal hypoxic–ischemic injury , 2005, Behavioural Brain Research.

[44]  Michael Recht,et al.  Long-term safety and efficacy of factor IX gene therapy in hemophilia B. , 2014, The New England journal of medicine.

[45]  N. Philpott,et al.  Efficient gene delivery to the adult and fetal CNS using pseudotyped non-integrating lentiviral vectors , 2009, Gene Therapy.

[46]  S. Bijarnia-Mahay,et al.  Prenatal Diagnosis of Lysosomal Storage Disorders Using Chorionic Villi. , 2017, Methods in molecular biology.

[47]  K. Foust,et al.  Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes , 2009, Nature Biotechnology.